REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO Inc. (Nasdaq: RGNX) announced its participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
REGENXBIO Inc. (Nasdaq: RGNX) announced its participation in two upcoming investor conferences. The Bank of America Securities 2022 Healthcare Conference will take place on May 10, 2022, at the Encore Hotel in Las Vegas, with a presentation scheduled for 4:00 p.m. PT. The UBS Global Healthcare Conference 2022 is set for May 24, 2022, at Lotte New York Palace, with a presentation at 10:45 a.m. ET. Webcasts of both events will be available on the REGENXBIO website for approximately 30 days following their presentations.
Details
News Market Reaction – RGNX
The recorded move for RGNX in the trading session of this news was +0.78%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., May 4, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:
Bank of America Securities 2022 Healthcare Conference
Date: Tuesday, May 10, 2022
Location: Encore Hotel, Las Vegas, NV
Presentation: Tuesday, May 10, 2022 at 4:00 p.m. PT
UBS Global Healthcare Conference 2022
Date: Tuesday, May 24, 2022
Location: Lotte New York Palace, New York, NY
Presentation: Tuesday, May 24, 2022 at 10:45 a.m. ET
A webcast of both presentations can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the presentation.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301539404.html
SOURCE REGENXBIO Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.